

(10) International Publication Number
WO 2014/015416 A1(43) International Publication Date
30 January 2014 (30.01.2014)

(51) International Patent Classification:

A61K 31/5685 (2006.01) A61P 15/02 (2006.01)
A61P 15/00 (2006.01) A61P 15/12 (2006.01)

(21) International Application Number:

PCT/CA2013/000654

(22) International Filing Date:

19 July 2013 (19.07.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/675,717 25 July 2012 (25.07.2012) US
13/942,977 16 July 2013 (16.07.2013) US

(71) Applicant: **ENDORECHERCHE, INC.** [CA/CA]; 2989, de la Promenade, Québec City, Québec G1W 2J5 (CA).(72) Inventor: **LABRIE, Fernand**; 2989, de la Promenade, Québec City, Québec G1W 2J5 (CA).(74) Agent: **BERESKIN & PARR LLP/S.E.N.C.R.L., S.R.L.**; Scotia Plaza, 40 King Street West, 40th Floor, Toronto, Ontario M5H 3Y2 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: IMPROVEMENT OF SEXUAL AROUSAL, SEXUAL DESIRE, ORGASM AND/OR PLEASURE FOLLOWING INTRAVAGINAL PRASTERONE (DHEA) ADMINISTRATION IN WOMEN NOT SUFFERING OR INDEPENDENTLY FROM DYSPAREUNIA OR OTHER SYMPTOMS OF VULVO-VAGINAL ATROPHY




Figure 1: Effect of daily intravaginal application of 0.0%, 0.25%, 0.5% and 1.0% dehydroepiandrosterone (DHEA; Prasterone) for 12 weeks on the score of sexual desire of the Menopause-Specific Quality of Life (MENQOL) questionnaire in postmenopausal women without or with moderate or severe pain at sexual activity at baseline. Data are also presented for the sum of the three prasterone doses. Data are expressed as means $\pm$ SEM; the p values are comparisons with placebo at all prasterone doses except for the placebo group (0% prasterone) which is compared to baseline.

(57) Abstract: Intravaginal DHEA is used for the treatment of at least one condition selected from the group consisting of female hypoactive sexual desire disorder, female sexual arousal disorder, female orgasm disorder and female sexual interest arousal disorder in a woman who either (1) is not suffering from symptoms of vulvo-vaginal atrophy and/or (2) is not suffering from moderate to severe dyspareunia.